Dissecting Mechanisms of Pyrimidine Synthesis Dependence in IDH Mutant Glioma
IDH 突变胶质瘤中嘧啶合成依赖性的剖析机制
基本信息
- 批准号:10612820
- 负责人:
- 金额:$ 3.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-20 至 2026-04-19
- 项目状态:未结题
- 来源:
- 关键词:AffectAstrocytesBiochemical PathwayBiologyBrainBrain NeoplasmsCell LineCell SurvivalCellsClinicClinical TrialsComplexDHODH geneDependenceDevelopmentDihydroorotate dehydrogenaseDiseaseDrug ScreeningDrug TargetingEnzyme InteractionEnzymesEquilibriumFellowshipGenesGliomaGlutamineHumanImmunofluorescence MicroscopyImmunoprecipitationIsocitrate DehydrogenaseLaboratoriesLinkMalignant NeoplasmsMass Spectrum AnalysisMeasuresMetabolicMetabolic PathwayMetabolismModelingMolecularMultienzyme ComplexesMutationNitrogenNormal CellOncogenesOncoproteinsPathway interactionsPatient SelectionPatientsPediatric OncologistPharmaceutical PreparationsPhenotypePhysiologicalPre-Clinical ModelProductionPyrimidinePyrimidine NucleotidesPyrimidinesRegulationRepressionResearchResistanceRoleRouteScientistStarvationTestingTherapeuticTrainingUridineUridine MonophosphateWestern BlottingWorkXenograft Modelcancer cellcareerdriver mutationenzyme biosynthesisexperimental studyin vivoinhibitorinhibitor therapyliquid chromatography mass spectrometrymutantneoplastic cellnerve stem cellnew therapeutic targetnitrogen metabolismnovelnovel therapeuticsnucleotide metabolismresearch clinical testingresponseresponse biomarkerstable isotopestem-like celltargeted treatmenttreatment strategytumor
项目摘要
PROJECT SUMMARY
Driver mutations in genes encoding the metabolic enzyme isocitrate dehydrogenase (IDH) are present in >80%
of lower-grade gliomas and the high-grade tumors that arise from them. To identify new therapeutic targets for
this incurable disease, our laboratory recently conducted an unbiased drug screen and discovered that IDH
oncogenes confer dependence on the de novo pyrimidine nucleotide synthesis pathway for glioma cell survival.
Despite our identification of this vulnerability, the molecular mechanism linking IDH mutations and dependence
on de novo pyrimidine nucleotide synthesis is unknown. Therefore, I developed a platform to comprehensively
profile nitrogen metabolism in patient-derived IDH mutant glioma stem-like cells (GSCs) treated with either
vehicle or an inhibitor of mutant IDH, identifying the contribution of glutamine to pyrimidine nucleotides as among
the most differentially regulated metabolic networks between these conditions. I subsequently found evidence of
disjunction between the two main routes for pyrimidine nucleotide production: de novo synthesis and salvage
pathways. Both pathways contribute to synthesis of uridine monophosphate (UMP), the metabolite from which
all other pyrimidine nucleotides are derived. My research revealed that although IDH mutant GSCs use both
pathways to produce UMP, these cells preferentially use UMP derived from the de novo pathway to synthesize
pyrimidine nucleotides downstream of UMP. This phenotype was not observed in human astrocytes, suggesting
that it may be tumor specific. I hypothesize that IDH mutant glioma cells are dependent on de novo pyrimidine
synthesis because they harbor a novel metabolic enzyme complex that channels UMP from the de novo
synthesis pathway to downstream pyrimidines. I will test this hypothesis through three studies. First, I will
evaluate whether this pyrimidine synthesis partitioning phenotype is unique to IDH mutant GSCs by performing
stable isotope tracing studies across a panel of IDH mutant and IDH wild-type patient-derived GSCs. Second, I
will test whether pyrimidine biosynthesis enzymes form a complex in IDH mutant GSCs but not in human
astrocytes using immunofluorescence microscopy and immunoprecipitation with Western blotting. Third, I will
test the relevance of pyrimidine synthesis pathway disjunction for de novo pyrimidine synthesis inhibitor therapy
with in vivo stable isotope tracing. I will perform these experiments in conjunction with treatment with a de novo
pyrimidine synthesis inhibitor in a patient-derived orthotopic xenograft model of IDH mutant glioma. The
proposed research has the potential to uncover new modes of regulation of nucleotide metabolism and answer
vital mechanistic questions surrounding a new synthetic lethality-based treatment strategy that is poised to enter
clinical testing in patients with IDH mutant glioma.
项目总结
代谢酶异柠檬酸脱氢酶(IDH)编码基因的驱动突变存在于80%
低级别胶质瘤和由此产生的高级别肿瘤。寻找新的治疗靶点
对于这种不治之症,我们实验室最近进行了无偏药物筛选,发现IDH
癌基因依赖于从头开始的嘧啶核苷酸合成途径来维持胶质瘤细胞的生存。
尽管我们发现了这种脆弱性,但将IDH突变和依赖联系起来的分子机制
从一开始,嘧啶核苷酸的合成是未知的。因此,我开发了一个平台来全面地
两种药物对IDH突变型胶质瘤干细胞(GSCs)氮代谢的影响
载体或突变型IDH的抑制剂,鉴定谷氨酰胺对嘧啶核苷酸的贡献如下
这些疾病之间调控差异最大的新陈代谢网络。后来我找到了证据
嘧啶核苷酸生产的两条主要途径:从头合成和回收
小路。这两条途径都有助于尿苷一磷酸(UMP)的合成,UMP是尿苷一磷酸的代谢物
所有其他的嘧啶核苷酸都是衍生出来的。我的研究表明,尽管IDH突变的GSC使用两者
产生UMP的途径,这些细胞优先使用来自从头途径的UMP来合成
UMP下游的嘧啶核苷酸。在人类星形胶质细胞中没有观察到这种表型,这表明
它可能是肿瘤特异性的。我推测IDH突变的胶质瘤细胞依赖于从头开始的嘧啶。
合成,因为它们含有一种新的代谢酶复合体,可以从从头开始引导UMP
合成下游嘧啶类化合物的途径。我将通过三项研究来检验这一假设。首先,我会
评估这种嘧啶合成分配表型是否是IDH突变的GSCs所特有的
一组IDH突变型和IDH野生型患者来源的GSCs的稳定同位素示踪研究。第二,我
将测试嘧啶生物合成酶是否在IDH突变的GSCs中形成复合体,但在人类中不形成
用免疫荧光显微镜观察星形胶质细胞,用Western blotting进行免疫沉淀。第三,我会
检测嘧啶合成途径脱节与从头治疗的相关性
体内稳定的同位素示踪。我将在进行这些实验的同时使用一种新的治疗方法
患者来源的IDH突变型胶质瘤原位异种移植模型中的嘧啶合成抑制剂。这个
拟议中的研究有可能发现核苷酸新陈代谢的新调节模式并回答
围绕着一种新的基于合成致命性的治疗策略的关键机制问题即将进入
IDH突变型胶质瘤患者的临床检测。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Milan Rashmin Savani其他文献
Milan Rashmin Savani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Milan Rashmin Savani', 18)}}的其他基金
Dissecting Mechanisms of Pyrimidine Synthesis Dependence in IDH Mutant Glioma
IDH 突变胶质瘤中嘧啶合成依赖性的剖析机制
- 批准号:
10464833 - 财政年份:2022
- 资助金额:
$ 3.9万 - 项目类别:
相似国自然基金
Ascl1介导Wnt/beta-catenin通路在TLE海马硬化中反应性Astrocytes异常增生的作用及调控机制
- 批准号:31760279
- 批准年份:2017
- 资助金额:35.0 万元
- 项目类别:地区科学基金项目
相似海外基金
The contribution of astrocytes in behavioral flexibility
星形胶质细胞对行为灵活性的贡献
- 批准号:
24K18245 - 财政年份:2024
- 资助金额:
$ 3.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Genetically-Encoded, Non-Invasive and Wireless Modulation of Calcium Dynamics in Astrocytes With Spatiotemporal Precision and Depth
具有时空精度和深度的星形胶质细胞钙动态的基因编码、非侵入性无线调节
- 批准号:
10562265 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
DNA methylation signatures of Alzheimer's disease in aged astrocytes
老年星形胶质细胞中阿尔茨海默病的 DNA 甲基化特征
- 批准号:
10807864 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
Elucidating endolysosomal trafficking dysregulation induced by APOE4 in human astrocytes
阐明人星形胶质细胞中 APOE4 诱导的内溶酶体运输失调
- 批准号:
10670573 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
Accelerating Functional Maturation of Human iPSC-Derived Astrocytes
加速人 iPSC 衍生的星形胶质细胞的功能成熟
- 批准号:
10699505 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
Defining cell type-specific functions for the selective autophagy receptor p62 in neurons and astrocytes
定义神经元和星形胶质细胞中选择性自噬受体 p62 的细胞类型特异性功能
- 批准号:
10676686 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
Astrocytes control the termination of oligodendrocyte precursor cell perivascular migration during CNS development
星形胶质细胞控制中枢神经系统发育过程中少突胶质细胞前体细胞血管周围迁移的终止
- 批准号:
10727537 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
Multispectral Imaging of Neurons and Astrocytes: Revealing Spatiotemporal Organelle Phenotypes in Health and Neurodegeneration
神经元和星形胶质细胞的多光谱成像:揭示健康和神经退行性疾病中的时空细胞器表型
- 批准号:
10674346 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
The role of lateral orbitofrontal cortex astrocytes in alcohol drinking
外侧眶额皮质星形胶质细胞在饮酒中的作用
- 批准号:
10823447 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别:
Investigating the role of diazepam binding inhibitor (DBI) in astrocytes and neural circuit maturation
研究地西泮结合抑制剂 (DBI) 在星形胶质细胞和神经回路成熟中的作用
- 批准号:
10567723 - 财政年份:2023
- 资助金额:
$ 3.9万 - 项目类别: